Novartis CEO Narasimhan Is Encouraged On US Drug Pricing Ahead Of Trump's Announcement
Executive Summary
New CEO offers his perspective on potential US drug pricing policy changes, including changes to Medicare Part B and pricing transparency. Pharma must also think more about social responsibility, he says, wading into a topic that will certainly be an issue for the new generation of industry leaders.